Director Sells Shares of Palvella Therapeutics, Inc. Amid Price Objective Setting

Director George Jenkins sold 7,174 shares of Palvella Therapeutics, Inc. on October 13th. The shares were sold at an average price of $130.36, totaling $935,202.64. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Palvella Therapeutics, Inc. recently posted quarterly earnings that missed the consensus estimate.

The sale by George Jenkins reduced his direct ownership position in Palvella Therapeutics, Inc. by 4.88%. Following the transaction, Palvella Therapeutics, Inc. stock traded down $5.93, while the company continues to face analyst forecasts for negative earnings per share.